SCHEMBL4580845

SCHEMBL4580845

O=C(O)c1ccc2cncc(Nc3ccccc3)c2n1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 4/20 0.46
KDM4E B2RXH2 1/20 0.43
KMT2A Q03164 1/20 0.43
MGAM O43451 1/20 0.42
MAPT P10636 1/20 0.42
GFER P55789 1/20 0.42
NGLY1 Q96IV0 1/20 0.42
CCNC P24863 1/20 0.41
CDK8 P49336 1/20 0.41
ADRA2A P08913 1/20 0.41
ADRA2B P18089 1/20 0.41
ADRA2C P18825 1/20 0.41
ADRA1A P35348 1/20 0.41
FABP4 P15090 1/20 0.41
KDM4C Q9H3R0 1/20 0.40
MAP3K8 P41279 1/20 0.40
PIM1 P11309 1/20 0.39
P4HTM Q9NXG6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4579533 0.90 ADRA2A (0.47) MMP2KDM4EKMT2ACCNCCDK8
SCHEMBL4582757 0.89 GSK3A (0.42) MMP2KDM4EKMT2ACCNCCDK8
SCHEMBL14368822 0.89 AKR1C3 (0.40) MMP2KMT2AMAPTGFERNGLY1
SCHEMBL4580442 0.87 P4HTM (0.43) MMP2KDM4EKMT2AMAPTGFER
SCHEMBL4581123 0.84 TAS2R14 (0.43) MMP2KDM4ECCNCCDK8
SCHEMBL4580475 0.84 AKR1C3 (0.48) KMT2AMAPTPIM1P4HTM
SCHEMBL4581447 0.83 CCNC (0.39) MMP2KDM4EKMT2AMAPTCCNC
SCHEMBL5183236 0.83 MPO (0.50) MMP2KMT2A
SCHEMBL4580993 0.78 KDM4E (0.41) MMP2KDM4EKMT2AMAPTCCNC
SCHEMBL4579023 0.77 ALDH1A1 (0.50) KDM4EKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives SERENEX, INC. 2008-02-07 US claimed
US-7282506-B2 2,8-disubstituted naphthyridine derivatives SERENEX, INC. (US) 2007-10-16 US claimed
EP-1773834-A2 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES Serenex, Inc. (US) 2007-04-18 EP claimed
WO-2006017672-A2 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES SERENEX INC. (US) 2006-02-16 WO claimed
US-20060030584-A1 2,8-Disubstituted naphthyridine derivatives SERENEX, INC. 2006-02-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030584-A1 2,8-Disubstituted naphthyridine derivatives CCNA1, FOXM1, CCNA2 MMP2 900/4885KDM4E 3744/4885KMT2A 2613/4885
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives CCNA1, FOXM1, CCNA2 MMP2 900/4885KDM4E 3744/4885KMT2A 2613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.